Track COMPASS Pathways plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

COMPASS Pathways plc CMPS · Stock Open COMPASS Pathways plc in new tab

8.05 USD
EPS
-2.34
P/B
8.20
ROE
-296.45
Beta
2.41
Target Price
23.31 USD
COMPASS Pathways plc logo

COMPASS Pathways plc

🧾 Earnings Recap – Q3 2026

Compass’s shares rose 2.1% after the earnings call, a roughly flat reaction. The update centered on completing the COMP360 NDA submission, FDA engagement, and preparations for a potential 2027 launch; approval timing and commercial uptake remain key uncertainties.

  • Compass expects to complete its rolling NDA submission within two weeks, supported by two Phase III studies and a Phase IIb study that together enrolled more than 1,000 patients.
  • The National Priority Voucher sets a one-to-two-month FDA review target, but the company described approval as a possibility, not a certainty.
  • Compass reported $444 million in cash as of September 30 and said it expects funds to carry it through launch and into 2028.
  • Commercial preparations continue: non-field commercial roles are filled, hiring for the field force is underway, and payer and clinician engagement is ongoing.
  • The registrationally designed PTSD trial is actively enrolling; Compass cited PTSD as a potential label expansion opportunity alongside its TRD launch focus.
📅
Loading chart...
Key Metrics
Earnings dateMarch 4, 2027
EPS-2.34
Book Value1.00
Price to Book8.20
Debt/Equity38.29
% Insiders9.610%
Estimates
Forward P/E-5.70
Forward EPS-1.44
Target Mean Price23.31

DCF valuation

Model fair value for COMPASS Pathways plc (CMPS)
Result
Sign in to run the valuation for CMPS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
16 analysts · consensus Strong buy · mean target 23.31 USD (low 10.00, high 65.00) · as of 16 Nov 2026
Low 10.00
Mean 23.31
High 65.00
Price 8.05
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

COMPASS Pathways plc Logo COMPASS Pathways plc Analysis (CMPS)

United Kingdom Health Care Official Website Stock

Is COMPASS Pathways plc a good investment? COMPASS Pathways plc (CMPS) is currently trading at 8.05 USD. Market analysts have a consensus price target of 23.31 USD. This suggests a potential upside from current levels.

Earnings Schedule: COMPASS Pathways plc is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is -1.44.

Investor FAQ

Does COMPASS Pathways plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is COMPASS Pathways plc?

COMPASS Pathways plc is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of -2.34.

Company Profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Exchange Ticker
FRA (Germany) 5Y6.F
NMS (United States) CMPS
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion